A Randomized Study Evaluating the Incidence of Post Lumbar Puncture Headache With Atraumatic Needles in Hematology
NCT03126045 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 68
Last updated 2022-02-08
Summary
Lumbar punctures are implemented for the diagnosis of patients with hematologic symptoms as well as for the intrathecal chemotherapy injections. Post lumbar puncture headache is a common complication for patients and is characterized by the occurrence of a headache with an orthostatic component, with additional symptoms such as nausea. Some studies in neurology, anesthesia and gynecology have previously shown a decreased incidence for post lumbar puncture headache while using atraumatic needles as compared to standard needles. In this context, it is necessary to better document the incidence of post lumbar puncture headache with the use of atraumatic needles in hematologic patients.
Conditions
Interventions
- DEVICE
-
Standard needle
Patients will perform a spinal punction with a standard needle, used in the usual practice. The standard needles have the following characteristics : BD 22 G x 3 ½ in, 90mm, Quincke spinal needle, Black hub. When more than 2 attempts for lumbar puncture fail, the investigator will proceed with standard techniques (BD 20G x 3 ½ in, Quincke spinal needle, 90mm, yellow hub). This is a failed lumbar puncture.
- DEVICE
-
Atraumatic needle
Patients will perform a spinal punction with an atraumatic needle, used in the hematological service of the CHU of Saint-Etienne. The atraumatic needles have the following characteristics : Vygon 24 G × 3 ½ in, 90mm, Whitacre Pencil Point Spinal Needle, Purple hub. When more than 2 attempts for lumbar puncture fail, the investigator will proceed with standard techniques (BD 20G x 3 ½ in, Quincke spinal needle, 90mm, yellow hub). This is a failed lumbar puncture.
Sponsors & Collaborators
-
Institut de Cancérologie de la Loire
collaborator OTHER -
Centre Hospitalier Universitaire de Saint Etienne
lead OTHER
Principal Investigators
-
Denis Guyotat, PhD · CHU de Saint-Etienne
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-08-22
- Primary Completion
- 2020-10-20
- Completion
- 2020-10-31
Countries
- France
Study Locations
More Related Trials
-
Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilimab for Primary Central Nervous System Lymphoma
NCT07198464 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy
NCT01452334 ·Status: WITHDRAWN ·Phase: PHASE1
-
Methotrexate and Temozolomide Versus Methotrexate, Procarbazine, Vincristine and Cytarabine
NCT00503594 ·Status: UNKNOWN ·Phase: PHASE2
-
Application of Telemedicine to the Management of Aggressive Lymphomas
NCT03336138 ·Status: COMPLETED ·Phase: NA
-
Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma
NCT01956695 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Localized Low Grade Lymphomas
NCT00536458 ·Status: COMPLETED ·Phase: PHASE3
-
Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma
NCT00794261 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma
NCT03391466 ·Status: COMPLETED ·Phase: PHASE3
-
Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma
NCT00335140 ·Status: TERMINATED ·Phase: PHASE2
-
Plerixafor Plus Granulocyte Colony-Stimulating Factor For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Non-Hodgkin Lymphoma
NCT02221492 ·Status: COMPLETED ·Phase: PHASE2
-
Elderly Hodgkin Lymphoma Patients Treated With Chemoradiotherapy
NCT03535948 ·Status: UNKNOWN
-
Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation
NCT01339572 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NCT02729896 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma
NCT00003338 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
High-dose Intravenous Methotrexate Versus Intrathecal Methotrexate for Central Nervous System Prophylaxis in DLBCL
NCT03123718 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor
NCT03235544 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+
NCT01354457 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Transplantation After Complete Response In Patients With T-cell Lymphoma
NCT05444712 ·Status: RECRUITING ·Phase: NA
-
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
NCT04245839 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
NCT01232556 ·Status: TERMINATED ·Phase: PHASE3
-
A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis
NCT00210340 ·Status: WITHDRAWN ·Phase: PHASE1
-
Impact of Immunotherapy on Vestibular Function, The Mayo Clinic Arizona Experience
NCT07307833 ·Status: ENROLLING_BY_INVITATION
-
Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma
NCT03761056 ·Status: COMPLETED ·Phase: PHASE2
-
Long-Term Follow-up of Tandem High-Dose Therapy With Peripheral Blood Stem Cell for Adults With High-Risk Age-Adjusted IPI Aggressive Non-Hodgkin's Lymphomas
NCT00869284 ·Status: COMPLETED ·Phase: PHASE2
-
Long-Term Follow-up Study
NCT05332054 ·Status: ENROLLING_BY_INVITATION